New Data On Delamanid Shows Promising Effects On XDR-TB Treatment

This week's New England Journal of Medicine published promising data on the efficacy of one of the newly developed anti-TB compounds for extensively drug-resistant tuberculosis (XDR-TB).The new data showed that XDR-TB patients receiving Delamanid in addition to a WHO- recommended optimized background regimen (OBR), had a higher proportion of 2-month sputum culture conversion (SCC) compared to XDR-TB patients receiving placebo plus OBR alone. As a result, patients who received Delamanid had more than 2 times greater likelihood of a successful treatment outcome.
Source :      2015/7/27 09:46

خانه چاپ ارسال به دوستان نسخه متنی کوچک کردن متن بزرگ کردن متن دانلود خروجی پی دی اف خروجی میکروسافت ورد
0/10 (تعداد آرا 0 نفر )
Copyright © 2011 AASM. All Rights Reserved.